BNSO yields 44.64% · ABBV yields 3.06%● Live data
📍 BNSO pulled ahead of the other in Year 1
Combined, BNSO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BNSO + ABBV for your $10,000?
Bonso Electronics International Inc., together with its subsidiaries, designs, develops, produces, and sells electronic sensor-based and wireless products. It operates in four segments: Scales, Pet Electronic Products, Rental and Management, and Others. The Scales segment provides sensor-based scales products that include bathroom, kitchen, office, jewelry, laboratory, postal, and industrial scales for consumer, commercial, and industrial applications. The Pet Electronic Products segment develops and produces pet-related electronic products for use in consumer applications. The Rental and Management segment offers leasing of factories and machineries to third parties. The Others segment sells cordless leaf blowers, food vacuum sealers, and hydroponics growing systems, as well as scrap materials; and provides tooling and molding charges for scales. It serves private label original equipment, original brand manufacturers, and original design manufacturers primarily in the United States, Germany, and the People's Republic of China. The company also sells its pet electronic products through online platforms. The company was formerly known as Golden Virtue Limited and changed its name to Bonso Electronics International Inc. in September 1988. Bonso Electronics International Inc. was incorporated in 1988 and is based in Tsim Sha Tsui, Hong Kong.
Full BNSO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.